Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
| Revenue (TTM) | $22.48B |
| Gross Profit (TTM) | $10.55B |
| EBITDA | $6.12B |
| Operating Margin | 15.70% |
| Return on Equity | 6.61% |
| Return on Assets | 4.34% |
| Revenue/Share (TTM) | $79.76 |
| Book Value | $89.64 |
| Price-to-Book | 2.05 |
| Price-to-Sales (TTM) | 2.21 |
| EV/Revenue | 2.938 |
| EV/EBITDA | 13.42 |
| Quarterly Earnings Growth (YoY) | -31.40% |
| Quarterly Revenue Growth (YoY) | 5.40% |
| Shares Outstanding | $272.39M |
| Float | $271.65M |
| % Insiders | 0.43% |
| % Institutions | 99.55% |
Volatility is currently contracting
FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.
BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Becton Dickinson (BDX) came out with quarterly earnings of $3.23 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $3.68 per share a year ago.
Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance FRANKLIN LAKES, N.J., Aug. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDX and any ticker you trade — then tracks every position and per-strategy win rate.
